Combined treatment ups breast cancer survival

By contrast, preventing the secretion of estrogen from the ovaries seems to offer no benefit for most women

In the ABC Chemotherapy trial, Dr. Judith Bliss, from The Institute of Cancer Research in Sutton, UK, and colleagues assessed the outcomes of 1991 patients, between 28 and 81 years of age, who received prolonged (5 years) tamoxifen therapy with or without standard chemotherapy. Some of the premenopausal women were also treated with ovarian removal (ablation) or suppression, which stops the glands from secreting hormones.

The chemotherapy group experienced fewer recurrences of their cancer than the comparison group, but the difference fell short of statistical significance, according to the report in the Journal of the National Cancer Institute. Still, chemotherapy did reduce the overall risk of death by 17 percent.

The benefit of chemotherapy in reducing cancer recurrence emerged early, while it took at least 5 years for the survival benefit to become apparent, the researchers note.

Further analysis showed that chemotherapy provided the greatest survival benefit in women younger than 50 years, especially premenopausal women not treated with ovarian ablation or suppression.

To better understand the benefits, if any, of ovarian ablation/suppression, Bliss’ team conducted the ABC Ovarian Ablation or Suppression trial, which involved 2144 women, who were premenopausal or just beginning menopause, who were given tamoxifen, with or without chemotherapy, and were randomly selected to receive or not receive ovarian ablation/suppression.

Ovarian ablation/suppression provided no improvement in survival, nor reduced cancer recurrences, the report indicates.

Subscribe to The China Post and save 25%. Click here

SharePrintEmail

Write a Comment

Enter your comments - 3000 characters max

Type in image code

Submit

 Receive China Post promos Respond to this email